SEC Tracker
Get the app

Upstream Bio UPB

Upstream Bio reports Q3 2026 financial results

Upstream Bio (UPB) filed an 8-K with the SEC on Nov 10, 2026, 7:05 am ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash, cash equivalents, and short-term investments: $207.4 million as of September 30, 2026
  2. R&D expenses: $36.6 million for Q3 2026, up from $33.0 million in Q3 2025
  3. Net loss: $41.2 million for Q3 2026, up from $33.7 million in Q3 2025

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Upstream Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.